In these head-to-head comparisons, we observed that in only KRAS mutant cell-derived xenograft models, that is, MIA PaCa-2- (Figure 2F) and BxPC-3 KRASG12V- (Figure 2H) derived models, DEX-TP outperformed free TP with higher tumor growth inhibition rates. The gene discussed is KRAS; the disease is neoplasm.